Experimental evidence from human AD tissue and studies involving selective purinergic receptor agonists and antagonists in vitro and in AD animal models have revealed that purinergic receptors represent novel therapeutic targets in AD [33]. The gene discussed is P2RX4; the disease is Alzheimer disease.